Shanghai – October 30, 2026 -- aphranel®, the regenerative aesthetics brand of MOYOM Biotech, has brought European physicians to China for a week-long clinical exchange, following NMPA Class III approval for its MagiCCrystal CaHA filler in China in 2025 and EU MDR certification in 2026.

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.